Kornimate/medical-research-clean huggingface dataset:
investigation of the validity, reliability, and responsiveness of the bety-bq in myositis

Conditions: Myositis

Summary: individuals diagnosed with myositis have skin, joint, and visceral organ involvement together with proximal muscle weakness, impaired physical function, sexual function, and quality of life also affect individuals psychosocially. increased anxiety-depression-anxiety problems are observed in individuals, and many factors contributing to these conditions are reported. therefore, while holistic evaluation of individuals, including these factors, gains importance, more information on how the quality of life changes during the disease is required. there is a need for tools to evaluate these characteristics in individuals disease management and treatment process. the cognitive exercise therapy approach (bilişsel egzersiz terapi yaklaşımı-bety) is an innovative exercise model based on physical exercise and an example of a biopsychosocial approach developed in patients with rheumatism. the bety-biopsychosocial questionnaire (bety-bq) was created by repeated statistics of the improvement characteristics reported by individuals who participated in bety sessions for many years. the bety-bq holistically evaluates many biopsychosocial characteristics of the individual, such as pain, coping skills, functionality, mood, sociability, sexuality, and sleep. therefore, there is a need for scales that holistically evaluate the symptoms mentioned in myositis disease. since the bety-bq can assess biopsychosocial characteristics quickly and its structure was created with the feedback of individuals with chronic disease, it aimed to examine its validation in this disease group. this study, which the investigators planned to contribute to this field, aims to investigate bety-bq\^s validity, reliability, and responsiveness in individuals diagnosed with myositis.


Eligibility criteria:
inclusion criteria: * diagnosis of myositis * to be over 18 years old * consent of the participant exclusion criteria: * uncontrolled/other clinically significant disease (chronic obstructive pulmonary disease, congestive heart failure, endocrine system diseases, neurological, psychological diseases, etc.) individuals with a diagnosis, * pregnant individuals, * individuals with malignancy

Keywords: myositis biopsychosocial model validity and reliability bety-bq muscle strenght pain
clinical study of manpixiao in the treatment of chronic atrophic gastritis

Conditions: Chronic Atrophic Gastritis

Summary: to explore the efficacy and safety of "manpixiao" in the treatment of chronic atrophic gastritis.


Eligibility criteria:
inclusion criteria: * the age is 18-75 years old, regardless of gender; * before treatment, the patients were diagnosed as chronic atrophic gastritis (with intestinal metaplasia and dysplasia) by gastroscopy and pathological examination, which met the criteria of the chinese consensus on chronic gastritis (2017, shanghai); * sign the informed consent form. exclusion criteria: * patients with autoimmune gastritis (chronic atrophic gastritis type a), peptic ulcer (a1-h2), reflux esophagitis, gastric polyps, hypertrophic gastritis and other diseases; * patients with high-grade intraepithelial neoplasia of gastric mucosa, suspected malignant change of gastrointestinal mucosal lesions, and gastrointestinal tumors; * patients with malignant tumors who have undergone surgery, radiotherapy and chemotherapy in recent 5 years; * patients with primary diseases such as heart, brain, lung, hematopoietic system and malignant tumors, and subjects with severe diabetes; * patients with chronic liver and kidney dysfunction before treatment, including alt \> 1.5 times the upper limit of normal value, blood creatinine (cr) \> 1.5 times the upper limit of normal value, and platelets lower than 1.5 times the lower limit of normal value; * disabled subjects specified by law (blind, deaf, dumb, intellectual, mental, physical disabilities); * the description of self symptoms is unclear or the investigation is not the author; * have a history of alcohol abuse; * allergic constitution or a history of allergy to multiple drugs (more than two or known ingredients in the drug); * pregnant or lactating women; * according to the judgment of the researcher, other reasons should not be selected.
open mesh versus suture repair in treatment of abdominal wall hernias

Conditions: Abdominal Hernia

Summary: the purpose of this study is to: 1. compare the long term results of mesh versus suture repair in treatment of abdominal wall defects; 2. find the optimal location of implanted prosthesis, comparing the two most useful position of mesh in abdominal wall hernia surgery.

to determine difference of operation time, applied materials of hernia operations; clinical complications, postoperative pain, hernia recurrence, recovery and normal activity time after surgery.

Eligibility criteria:
inclusion criteria: * during the two-year randomization period at the joined centres all patients were included who were admitted with abdominal wall or umbilical hernia and who suited the requirements. * all the patients with primer or first recurrence of postoperative abdominal or primer or first recurrence of umbilical hernia were randomized into this study. * for involvement into the study good patient compliance, signed consent form, normal local circumstances were needed. exclusion criteria: * ages fewer than 18 or above 70 years * hernia orifice under 5 cm2. * planned or accidental intraoperative opening of any bowel. * unstable parameters of circulation, uncontrollable diabetic or autoimmune disease. * severe renal or hepatic failure * advanced stage of tumours or currently treated malignancies. * inflamed or muddy content of hernia sac. * if the patient did not signed the consent form.

Keywords: position of the mesh recurrence rate surgical procedure long time outcome
self-compassion to enhance the well-being of caregivers of children with physical disabilities

Conditions: Stress; Caregiver Burden; Anxiety; Depressive Symptoms

Summary: the goal of this clinical trial is to test the feasibility, acceptability and preliminary social/emotional well-being outcomes of a tailored, online self-compassion-based resilience course for caregivers of children with physical disabilities. the main questions it aims to answer are: 1. is the online resilience course feasible and acceptable to caregivers of children with physical disabilities? 2. is participation in the resilience course associated with improvements in caregiver stress, anxiety, depression, burden, caregiver uplifts, self-compassion, emotion regulation and/or resilience? participants will complete a screening, a verbal consent process and an electronic pre-course survey. then, they will participate in a 6-session weekly online course with other caregivers and led by a certified mindful self-compassion instructor. the course has been created with feedback from caregivers and includes skills for recognizing and coping with difficult emotions while connecting with others who have similar caregiving experiences. after the course, participants will repeat the electronic survey and will provide feedback on the course during a live, online feedback session.


Eligibility criteria:
inclusion criteria: * caregiver is at least 18 years old * caregiver reads and speaks in english * caregiver is a primary caregiver to a child aged 2-17 with a moderate to severe chronic physical disability (child requires assistance or adapted methods for mobility (e.g., walking, transfers) and at least 1 other functional area (e.g., toileting, feeding, communication)) exclusion criteria: * caregiver has no access to the internet/zoom * caregiver has been hospitalized in the last year for mental health treatment * caregiver has a history of psychosis (e.g., schizophrenia) * caregiver will miss 2 or more class sessions due to scheduling conflicts
simvastatin to prevent sci-induced bone loss

Conditions: Spinal Cord Injuries; Osteoporosis

Summary: this is a double blind, randomized, placebo -controlled clinical trial with the primary goal of determining the osteogenic benefits of simvastatin in acute sci.

investigators will test if a 1- year course of simvastatin (40 mg daily) will prevent bone loss compared to placebo in the first year following sci.

Eligibility criteria:
inclusion criteria: * 18-60 years of age * acute sci (ais a-c) who are enrolled at our center in an ongoing surveillance study. * use a wheelchair as their primary mobility mode * reside in the greater denver metropolitan area * within 3 months of injury * medically stable * able to follow directions * provide informed consent. exclusion criteria: - have any simvastatin contraindications including: * drug allergy, * active liver disease, * renal dysfunction, * concurrent use of drugs that cause myopathy or increase the risk of myopathy with simvastatin therapy (gemfibrozil, niacin, cyclosporine, danazol, amiodarone, dronedarone, ranolazine, calcium channel blockers, colchicine), strong cyp34a inhibitors (itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, hiv protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat-containing products), low plasma cholesterol levels, * uncontrolled or poorly controlled diabetes, * unstable anti-coagulation treatment, * taking a statin in the preceding 12 months, * metabolic bone disease, thyroid disorder, * history of bilateral oophorectomy, * current use of medications potentially affecting bone health including bisphosphonates, androgenic steroids, estrogenic steroids, anti-epileptics, lithium glucocorticoid use for more than 3 months, * have received inhaled glucocorticoids in the past 12 months, * pregnant or lactating women, * women of childbearing potential who are unwilling or unable to use a reliable form of contraception.
neurofeedback during eating for bulimia nervosa

Conditions: Bulimia Nervosa

Summary: the purpose of this study is to examine the effects of noninvasive prefrontal cortex (pfc) neurofeedback during eating in women with bulimia nervosa (bn) using a wearable brain imaging device, functional near-infrared spectroscopy (fnirs). the investigators will examine how this training may influence inhibitory control and bn symptoms.

the purpose of this study is to examine the effects of pfc neurofeedback during eating in women with bulimia nervosa (bn) using fnirs. specifically, the study aims 1) to demonstrate ventrolateral pfc (vlpfc) neurofeedback target engagement in women with bn using fnirs; and 2) to link changes in pfc activation to changes in inhibitory control and eating-related symptoms. data will be collected from women with bn who will be randomly assigned to one of two group conditions (real or sham-control neurofeedback during eating). participation includes a phone screening assessment, psychodiagnostic assessment, one in-person evaluation, one neurofeedback session, behavioral tasks, online questionnaires before and after the neurofeedback session, and a remote follow-up assessment.

Eligibility criteria:
inclusion criteria: * female * aged 18 to 45 years * meet diagnostic criteria for bulimia nervosa * current body mass index greater than or equal to 18.5kg/m2 but under 30kg/m2 * english-speaking exclusion criteria: * ongoing medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation * current psychotherapy focused primarily on eating disorder symptoms * pregnancy or planned pregnancy, or lactation during the study period * allergy to ingredients in the standardized meal or in the shake
a phase ii study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide

Conditions: Small Cell Lung Carcinoma

Summary: the primary aim of this study is to determine if the addition of valproic acid to a combination of adriamycin, cyclophosphamide and vindesine could increase progression-free survival in patients relapsing after first-line chemotherapy including platinum derivatives, cisplatin or carboplatin, and etoposide.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of small-cell lung cancer (sclc) * sclc refractory to prior chemotherapy regimen including platinum derivatives (cisplatin or carboplatin) and etoposide, either primary refractory (immediate progression or recurrence less than 3 months after the end of previous chemotherapy) or secondary refractory (sensitive patients to platinum plus etoposide in first-line, progressing or recurring less than 3 months after reintroduction of the same chemotherapy). * at least one evaluable or measurable lesion * availability for participating in the detailed follow-up of the protocol * signed informed consent. exclusion criteria: * patient who were previously treated with anthracyclin or vinca-alcaloid derivatives or cyclophosphamide * performance status \< 60 on the karnofsky scale * a history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval) * a history of prior hiv infection * polynuclear cells \< 2,000/mm³ * platelet cells \< 100,000/mm³ * abnormal coagulation tests (aptt, ptt, prothrombin time) and/or decreased fibrinogen * serum bilirubin \>1.5 mg/100 ml * transaminases more than twice the normal range * serum creatinine \> 1.5 mg/100 ml * recent myocardial infarction (less than 3 months prior to date of diagnosis) * congestive cardiac failure (ejection fraction of the left ventricle \< 50%) or uncontrolled cardiac arrhythmia * uncontrolled infectious disease * active epilepsy needing a specific treatment * concomitant treatment with imao, carbamazepine, mefloquine, phenobarbital, primidone, phenytoïn, lamotrigine, zidovudine * pregnancy or refusal to use active contraception * a known allergy to valproic acid and/or doxorubicin, cyclophosphamide, vindesine * serious medical or psychological factors which may prevent adherence to the treatment schedule.

Keywords: small cell lung carcinoma valproic acid adriamycin cyclophosphamide vindesine second-line chemotherapy
aflibercept and standard chemotherapy (r-chop) in first line of non hodgkin b-cell lymphoma

Conditions: Lymphoma, Non-Hodgkin

Summary: the purpose of this study is to determine the selected dose of aflibercept when it is combined with r-chop treatment (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone +/- intrathecal methotrexate) administered every 2 weeks or every 3 weeks, in non hodgkin b-cell lymphoma, and to determine how the body handles aflibercept when it is administered with r-chop.


Eligibility criteria:
inclusion criteria: * patients with non-hodgkin b-cell lymphoma, good condition, not previously treated exclusion criteria: * contraindication to any drug contained in the r-chop (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone +/- intrathecal methotrexate) * less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of inclusion * cerebral or leptomeningeal involvement. * history of another neoplasm (adequately treated basal cell or squamous cell skin cancers, carcinoma in situ of the cervix, or any other cancer from which the patient has been disease free for \> 5 years are allowed) * participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to the first drug intake * any acute or chronic medical condition, which could impair the ability of the patient to participate to the study or could interfere with interpretation of study results * uncontrolled diabetes mellitus * uncontrolled hypertension * abnormal kidney function * evidence of clinically significant bleeding diathesis, non-healing wound or underlying coagulopathy * pregnant or breast-feeding woman, or patient with reproductive potential (male, female) without an effective method of contraception * history of hypersensitivity to any trap agents or recombinant proteins

Keywords: non-hodgkin's lymphoma angiogenesis inhibitors chop protocol
augmented-reality cta plus angiography vs angiography alone for guiding pci in coronary lesions - randomized study

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to compare revascularization strategy and its immediate results after augmented-reality computed tomography angiography (cta) guided vs. standard angiography guided percutaneous coronary intervention (pci) in native coronary lesions.

while stand-alone angiography is the first-line imaging modality for guidance of pci, it has some inherent limitations which may result in suboptimal stent placement related to residual reference segment disease and stent underexpansion. coronary cta, on the other hand, can provide reliable measurements of the vessel size and lesion length as well as the visualization of the morphological features of coronary plaque, and has been suggested as potentially valuable for changing pci technique. the ar-pci trial has been designed as a single-center, investigator initiated and investigator sponsored, randomized (1:1), controlled, prospective clinical trial. it is hypothesized that the review of cta datasets using augmented-reality glass in the catheterization laboratory could influence pci treatment strategy and its immediate results by more adequate lesion coverage with less residual disease and better stent expansion as compared to traditional angiography-guided pci alone.

Eligibility criteria:
inclusion criteria: * patients with documented obstructive cad defined as the presence of at least 1 stenosis ≥70% in a native coronary artery in whom pci is considered based on clinical grounds exclusion criteria: * refusal or inability to provide written informed consent * subjects in whom the quality of coronary cta is insufficient * bifurcation lesions, by which strategies other than a single cross-over stent technique are anticipated * left main coronary artery stenosis * chronic total occlusion * in-stent restenosis * chronic renal failure (estimated glomerular filtration rate \<30 ml/min) * known allergy to contrast * untreated hyperthyroidism * pregnancy

Keywords: coronary stenosis percutaneous coronary intervention stents computed tomography angiography augmented reality
monitoring luminal breast cancer through the evaluation of mutational and epigenetic alterations of circulating esr1 dna

Conditions: Hormone Receptor Positive Breast Carcinoma; Breast Neoplasms; Neoplasms, Breast; Breast Diseases; Antineoplastic Agents; Aromatase Inhibitors; ESR1 Gene Mutation

Summary: the purpose of the study is to determine the diagnostic role of ctdna when used to monitor metastatic breast cancer (mbc) during first-line endocrine therapy.

patients with hormone receptor-positive mbc are eligible for endocrine therapy (et) as first line treatment which is based on strategies aimed to either block signaling pathways depending on the estrogen receptor (esr1) or using esr1 antagonists. only a few accepted predictive factors are associated with treatment benefit for mbc (i.e., hormone receptor status and her2 status). furthermore, a standardized assessment evaluation for mbc is still lacking. because of these unmet needs, et is continued until disease progression, or if toxicity requiring discontinuation occurs. resistance is frequent in the treatment of early bc and unavoidable in mbc. recently, mutations in esr1 have been described in mbc that had been previously exposed to aromatase inhibitors (ais) and are rarely detectable in primary bc. besides that, resistance phenomena have been also linked to esr1 cisregulatory elements (cre, i.e. enhancers and promoters) hypermethylation, both related to esr1 silencing. according to the literature, the aim of the study is to detect tumor response with liquid biopsy technique compared to conventional clinical pratice algorithms.

Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease. * er positive tumor ≥ 1% * her2 negative breast cancer by fish or ihc (ihc 0,1+, 2+ and/or fish her2: cep17 ratio \< 2.0) * females, 18 years of age or older * candidate to first-line endocrine therapy (lh-rh analogue for premenopausal women is allowed) * signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. * willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. exclusion criteria: * diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. * prior endocrine therapy for metastatic disease

Keywords: epigenetics liquid biopsy ctdna esr1 gene mutation biomarker hr-positive her2-negative advanced breast cancer cdk4/6 antineoplastic agents hormonal
fludarabine, cyclophosphamide, doxorubicin and rituximab for the treatment of post-transplant lymphoproliferative disease (ptld)

Conditions: Post-transplant Lymphoproliferative Disease (PTLD); Non Burkitt

Summary: fludarabine may be of benefit to prevent rejection of grafted solid organs in children during chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (ptlds).

eligible to this study were patients less than 18 years old, presenting with non burkitt, aggressive, cd20 positive ptld, after solid organ transplants. induction therapy consisted of two cycles of a combination of fludarabine(30mg/sqm/day, days 1,2,3), cyclophosphamide (750 mg/sqm/day, day 1), doxorubicin (30 mg/sqm/day, day 1)and rituximab (375 mg/sqm/day, day 4). thereafter consolidation therapy was given as follows: two blocks for stage ii or iii with ldh less than 500 iu/l; three blocks for stage iii with ldh \>500 and \ 1000 iu/l. blocks given were modified bfm blocks used for treatment of non hodgkin b-lymphomas, as follows: block 1: high dose methotrexate (hdmtx) 1.5 gr/sqm; vincristine (vcr,1.5 mg/sqm); cytarabine (from 120 to 150 mg/sqm x4); ifosfamide (600 mg/sqm/day x5); vp-16 (80 mg/sqm/day x2); dexamethasone (dxm,10 mg/sqm/day for 5 ays); intrathecal methotrexate-cytarabine-methylprednisolone(tit). block 2:hdmtx (3 gr/sqm); vcr (1.5 mg/sqm); daunomycin (20 mg/sqm/day x2); cyclophosphamide (160 mg/sqm/day x5); dxm (10 mg/sqm/day x5); tit block 3:vindesine (3 mg/sqm); cytarabine (3000 mg/sqm q 12 hours x4); vp-16 (100 mg/sqm q 12 hours x4); dxm (20 mg/sqm/day x5); block 4 as block 1. outcome measures are: achievement of complete remission after induction therapy; incidence of infectious episodes; neurological toxicity; incidence of graft rejection; duration of complete remission.

Eligibility criteria:
inclusion criteria: * children less 18 years old and * non burkitt, cd20 positive aggressive ptld and * solid organ transplant exclusion criteria: * burkitt ptld